Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
BioPlx Microbiomics Pvt Ltd
Debiopharm Intertiol SA
Destiny Pharma Plc
Galenus Therapeutics Inc
Genentech USA Inc
HyPharm GmbH
LegoChem Biosciences Inc
Lytix Biopharma AS
icons Srl
Sichuan Saizhuo Pharmaceutical Co Ltd
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01KS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01WT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftobiprole medocaril - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-010699 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
litazolid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LTX-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
I-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7861 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit D Gyrase and D Topoisomerase IV for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
Featured News & Press Releases
Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug "Ristazolone Dry Suspension"
Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Genentech USA Inc, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Lytix Biopharma AS, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, 2021
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, 2021